Brigatinib: A Review in ALK-Inhibitor Naïve Advanced ALK-Positive NSCLC
Abstract
Brigatinib (Alunbrig®) is an oral, potent and selective anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) tyrosine kinase inhibitor approved for treating adults with advanced ALK-positive non-small-cell lung cancer (NSCLC) not previously treated with an ALK inhibitor. In a multinational, phase III study (ALTA-1L) in this patient population, brigatinib significantly improved median blinded independent review committee-assessed...
Paper Details
Title
Brigatinib: A Review in ALK-Inhibitor Naïve Advanced ALK-Positive NSCLC
Published Date
Feb 1, 2021
Journal
Volume
81
Issue
2
Pages
267 - 275
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History